Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
Holding ENOV?
Track your performance easily
ENOV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.27 - $65.03
Previous Close$48.27
Volume401.40K
Average Volume (3M)653.86K
Market Cap
$2.64B
Enterprise Value$4.01B
Total Cash (Recent Filing)$35.42M
Total Debt (Recent Filing)$1.35B
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 20, 2025EPS Estimate
$0.92Last Dividend Ex-Date
Apr 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding55,875,456
10 Day Avg. Volume611,741
30 Day Avg. Volume653,857
Standard Deviation0.17
R-Squared0.50
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.75
Price to Sales (P/S)1.26
Price to Cash Flow (P/CF)11.80
P/FCF Ratio47.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit4.05
Enterprise Value/Ebitda22.56
Forecast
1Y Price Target
$65.86Price Target Upside39.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Enovis News
PremiumCompany Announcements
Enovis Corporation Reports Strong Sales Growth in Q3 2024
PremiumPre-Earnings
Is ENOV a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceENOV delivered a strong quarter, surpassing expectations on both revenue and earnings with a notable pro forma EPS of $0.73, exceeding consensus estimates.
Growth PotentialThe company's integration of the Lima acquisition is mostly complete, promising cost savings and sales synergies that are yet to be reflected in the stock's valuation, presenting an attractive opportunity for investors.
Market Position And StrategyEnovis is a leader in the prevention and recovery markets and is strengthening its position in the global orthopedic implant market, offering a unique opportunity for better outcomes and long-term monetization.
Bears Say
Competitive ConcernsSlower 2Q growth won't help address growing competitive concerns from investors regarding ENOV's U.S. shoulder business, and to a lesser extent U.S. hips/knees.
Growth And GuidanceLack of upside versus what looked like conservative 2Q guidance and slowing U.S. pro-forma growth is keeping a lid on investor sentiment.
Investor SentimentThe lack of beats and raises from ENOV has been a point of frustration for some investors.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $38.27 and its highest was $65.03 in the past 12 months.
What is Enovis’s market cap?
Currently, no data Available
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Feb 20, 2025 which is in 86 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Nov 06, 2024. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.616 by $0.114.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis pays a Notavailable dividend of $16.67 which represents an annual dividend yield of N/A. See more information on Enovis dividends here
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is $0.92.
How many shares outstanding does Enovis have?
Enovis has 55,875,458 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.73 in its last earnings report, beating expectations of $0.616. Following the earnings report the stock price went up 8.289%.
Which hedge fund is a major shareholder of Enovis?
Among the largest hedge funds holding Enovis’s share is Diamond Hill Capital Management Inc. It holds Enovis’s shares valued at 129M.
---
Enovis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.86 (39.36% Upside)
$65.86 (39.36% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 684.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.51%
12-Months-Change
Fundamentals
Return on Equity
-3.59%
Trailing 12-Months
Asset Growth
26.11%
Trailing 12-Months
Company Description
Enovis
Colfax Corp. operates as a diversified technology company that provides orthopedic care and fabrication technology products and services to customers. The firm operates its business through the following segments: Medical Technology; and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices with a broad range of products used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures, and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Annapolis Junction, MD.
---
ENOV Company Deck
---
ENOV Earnings Call
Q3 2024
0:00 / 0:00
---
ENOV Stock 12 Month Forecast
Average Price Target
$65.86
▲(39.36% Upside)
Technical Analysis
Best Analysts Covering ENOV
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+5.56%
reiterated a buy rating 2 months ago
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +5.56% per trade.
---